MICA · FIRST-LINE LEARNING NOTES
Understand, prioritise and organise follow-up
Check interactions when a product is started, stopped or changed. Clinical importance depends on the medicines, exposure and patient, rather than on an electronic alert alone.
Identify every exposure
Ask about every prescriber, non-prescription medicines, herbal products, supplements and occasional doses. Identify generic names and hidden combination ingredients. Check weekly regimens: low-dose methotrexate for autoimmune disease is usually taken once weekly, and inadvertent daily administration can be fatal. Confirm the indication before applying that rule.
[1]Understand the clinical consequence
Distinguish altered concentration, additive effects and regimen errors. With DOACs, some interactions increase exposure and bleeding, whereas enzyme inducers may reduce efficacy. Other combinations add bleeding risk without directly changing concentration. Check current product information and an updated interaction resource, then consider renal function, age, weight, comorbidity and combination duration.
[2]For an interaction, assess mechanism, potential severity, onset and alternatives. An electronic alert alone does not determine whether treatment should continue or stop. Verify high-risk weekly schedules, particularly methotrexate for inflammatory disease. Include herbal products, supplements and non-prescription medicines in reconciliation.
[2][1]Agree on an explicit response
An alert requires an action: an alternative, pharmacy or specialist advice, suitable monitoring or a documented rationale. Separating administration times does not resolve every interaction, particularly metabolic or bleeding effects. Warfarin with tramadol may increase INR and bleeding risk, so analgesics are not automatically harmless. Do not empirically adjust anticoagulants to offset an assumed interaction.
[3][2]- Check indication before changing a prescription; methotrexate schedules are not interchangeable across indications.
- Document the choice of substitution, adjustment or monitoring, including owner and timing.
- Suspected toxicity or accidental daily methotrexate use requires immediate specialist medical advice.
Plan monitoring after a change
Specify what to monitor, who is responsible and for how long, including after the interacting product is stopped. Explain symptoms to report and check that patients recognise high-risk medicines. With methotrexate, unusual mouth ulcers, infection or a dosing-frequency error require prompt medical contact. Suspected overdose or major bleeding requires emergency assessment.
[1][3]A learning situation
FICTIONAL CASE · SELF-REFLECTION WITHOUT A SCORE
A patient stable on warfarin receives tramadol from another prescriber. Bruising develops a week later. Neither the new prescriber nor the INR-monitoring team had the complete medicine list.
Which coordination failure needs correction?
Read the reasoning
The incomplete list prevented detection of a known interaction. Promptly assess bleeding, check INR as appropriate and coordinate management between prescribers. Explain the importance of reporting new medicines. Merely spacing tablets or independently reducing warfarin is not an adequate response.
References and scope
- Methotrexate once-weekly for autoimmune diseases: new measures to reduce risk of fatal overdose due to inadvertent daily instead of weekly dosing ↗
- Understanding direct oral anticoagulant (DOAC) interactions ↗
- Warfarin: be alert to the risk of drug interactions with tramadol ↗
Original educational synthesis for adult first-line practice. International references must be interpreted with the clinical setting and local care pathways. Independent human scientific review remains to be confirmed.